Tomas Kalincik

Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis.

Daniel Merlo, Jim Stankovich, Claire Bai, Tomas Kalincik, Chao Zhu, Melissa Gresle, Jeannette Lechner-Scott, Trevor Kilpatrick, Michael Barnett, Bruce Taylor, David Darby, Helmut Butzkueven, Anneke Van der Walt

Journal article  |  2021  |  Neurology

BACKGROUND AND OBJECTIVES: Longitudinal cognitive trajectories in multiple sclerosis are heterogeneous and difficult to measure. W..

Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry

Rachel Kenney, Mengling Liu, Sachi Patil, Raed Alroughani, Radek Ampapa, Roberto Bergamaschi, Cavit Boz, Helmut Butzkueven, Jose Cabrera Gomez, Elisabetta Cartechini, Sara Eichau Madueno, Diana Ferraro, Francois Grand-Maison, Franco Granella, Dana Horakova, Guillermo Izquierdo Ayuso, Tomas Kalincik, Jana Lizrova Preiningerova, Alessandra Lugaresi, Marco Onofrj, et al.

Journal article  |  2021  |  JOURNAL OF THE NEUROLOGICAL SCIENCES

BACKGROUND: Short-term outcomes of optic neuritis (ON) have been well characterized. Limited data exists on longer-term visual out..

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Steve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, Nick Rijke, Jan A Hillert, Clare Walton, Gilles Edan, Yves Moreau, Tim Spelman, Lotte Geys, Tina Parciak, Clement Gautrais, Nikola Lazovski, Ashkan Pirmani, Amin Ardeshirdavanai, Lars Forsberg, Anna Glaser, Robert McBurney, Hollie Schmidt, Arnfin B Bergmann, et al.

Journal article  |  2021  |  NEUROLOGY

BACKGROUND AND OBJECTIVES: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-1..

Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180].

Edward De Brouwer, Thijs Becker, Yves Moreau, Eva Kubala Havrdova, Maria Trojano, Sara Eichau, Serkan Ozakbas, Marco Onofrj, Pierre Grammond, Jens Kuhle, Ludwig Kappos, Patrizia Sola, Elisabetta Cartechini, Jeannette Lechner-Scott, Raed Alroughani, Oliver Gerlach, Tomas Kalincik, Franco Granella, Francois Grand'Maison, Roberto Bergamaschi, et al.

Journal article  |  2021  |  Comput Methods Programs Biomed

Subjective versus objective performance in people with multiple sclerosis using the MSReactor computerised cognitive tests.

Daniel Merlo, Tomas Kalincik, Chao Zhu, Melissa Gresle, Jeannette Lechner-Scott, Trevor Kilpatrick, Michael Barnett, Bruce Taylor, Katherine Buzzard, David Darby, Helmut Butzkueven, Anneke van der Walt

Journal article  |  2021  |  Multiple Sclerosis and Related Disorders

High BMI In Youths as a Modifiable Risk Factor for Multiple Sclerosis: Weighing Up the Evidence.

Tomas Kalincik, Helen Tremlett, Alberto Ascherio

Journal article  |  2021  |  Neurology

Prediction of multiple sclerosis outcomes when switching to ocrelizumab

Michael Zhong, Anneke van der Walt, Jim Stankovich, Tomas Kalincik, Katherine Buzzard, Olga Skibina, Cavit Boz, Suzanne Hodgkinson, Mark Slee, Jeannette Lechner-Scott, Richard Macdonell, Julie Prevost, Jens Kuhle, Guy Laureys, Liesbeth Van Hijfte, Raed Alroughani, Allan G Kermode, Ernest Butler, Michael Barnett, Sara Eichau, et al.

Journal article  |  2021  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: Increasingly, people with relapsing-remitting multiple sclerosis (RRMS) are switched to highly effective disease-modif..

Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis

Tomas Uher, Eva Kubala Havrdova, Pascal Benkert, Niels Bergsland, Jan Krasensky, Barbora Srpova, Michael Dwyer, Michaela Tyblova, Stephanie Meier, Manuela Vaneckova, Dana Horakova, Robert Zivadinov, David Leppert, Tomas Kalincik, Jens Kuhle

Journal article  |  2021  |  MULTIPLE SCLEROSIS JOURNAL

BACKGROUND: The added value of neurofilament light chain levels in serum (sNfL) to the concept of no evidence of disease activity-..

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

Vicki E Maltby, Rodney A Lea, Mastura Monif, Marzena J Fabis-Pedrini, Katherine Buzzard, Tomas Kalincik, Allan G Kermode, Bruce Taylor, Suzanne Hodgkinson, Pamela McCombe, Helmut Butzkueven, Michael Barnett, Jeannette Lechner-Scott

Journal article  |  2021  |  JMIR RESEARCH PROTOCOLS

BACKGROUND: Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently been listed on the pharmaceutica..

Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts

Sifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, Emmanuelle Leray, Dana Horakova, Eva Kubala Havrdova, Raed Alroughani, Guillermo Izquierdo, Serkan Ozakbas, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Murat Terzi, Pierre Grammond, Francois Grand'Maison, Bassem Yamout, Alexandre Prat, Marc Girard, Pierre Duquette, Cavit Boz, et al.

Journal article  |  2021  |  CNS DRUGS

INTRODUCTION: Natalizumab has proved to be more effective than fingolimod in reducing disease activity in relapsing-remitting mult..